3/6/2014 8:13:10 AM
Earlier this week in its annual report Aegerion Pharmaceuticals provided an update on its ongoing problems with the FDA and the Department of Justice. As previously reported here and on The Street and on CNBC, the company landed in hot water with the FDA last year after its CEO made a series of off-label statements on the CNBC Fast Money show.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by